MiR-210 targets VMP1, leading to its downregulation (Ying et al., 2011; Liu et al., 2014; Cui et al., 2015; Yang et al., 2021), which is associated with a pro-tumorigenic effect across various cancers, including lung adenocarcinoma (Cui et al., 2015), ovarian cancer (Liu et al., 2014) and hepatocellular carcinoma (Ying et al., 2011). This evidence concerns the gene VMP1 and cancer.